OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis → BlackRock Bets Big on Tiny Biotech (From Behind the Markets) (Ad) Free CSLLY Stock Alerts $91.43 -0.12 (-0.13%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$91.43▼$92.3050-Day Range$89.91▼$99.4152-Week Range$71.51▼$105.11Volume18,658 shsAverage Volume36,188 shsMarket Capitalization$88.34 billionP/E RatioN/ADividend Yield1.19%Price TargetN/A Stock AnalysisStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address CSL MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth14.29%From $3.15 to $3.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.62 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for CSL. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently increased by 443.75%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldCSL pays a meaningful dividend of 1.18%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 30.28% next year. This indicates that CSL will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSLLY. Previous Next 1.7 News and Social Media Coverage News SentimentCSL has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CSL this week, compared to 1 article on an average week.MarketBeat Follows2 people have added CSL to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.06% of the stock of CSL is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CSL are expected to grow by 14.29% in the coming year, from $3.15 to $3.60 per share.Price to Book Value per Share RatioCSL has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesMarch 11, 2024 | finance.yahoo.comCSL Ltd's Dividend AnalysisMarch 6, 2024 | prnewswire.comCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. SeasonMarch 19, 2024 | Behind the Markets (Ad)BlackRock Bets Big on Tiny BiotechAn undervalued biotech firm is on the verge of a major discovery - That has the potential to treat Alzheimer's, Parkinson's and Dementia. BlackRock is so confident in this firm, they've invested $298 million.February 15, 2024 | markets.businessinsider.comWilsons downgrades CSL (CMXHF) to a HoldFebruary 13, 2024 | fool.com.auCSL shares tumble despite first-half earnings beatFebruary 13, 2024 | afr.comWhat we learnt from CSL, Challenger, Seek and Breville’s resultsFebruary 13, 2024 | finanznachrichten.deCSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³February 12, 2024 | fool.com.auCSL share price on watch amid 20% profit jumpMarch 19, 2024 | Behind the Markets (Ad)BlackRock Bets Big on Tiny BiotechAn undervalued biotech firm is on the verge of a major discovery - That has the potential to treat Alzheimer's, Parkinson's and Dementia. BlackRock is so confident in this firm, they've invested $298 million.February 12, 2024 | marketwatch.comCSL Says 1H Profit Rises, Boosts Dividend -- UpdateFebruary 12, 2024 | afr.comCSL shrugs off trial setback to post double-digit earnings growthFebruary 12, 2024 | wsj.comCSL Profit Rises, Boosts DividendFebruary 12, 2024 | msn.comCSL Limited falls after Phase 3 setback for key trialFebruary 12, 2024 | msn.comAsian stocks move little in holiday-thinned trade; CSL drags on AustraliaFebruary 6, 2024 | msn.comCSL and Arcturus’ Covid-19 booster found to prolong immunityFebruary 5, 2024 | finance.yahoo.comNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterJanuary 29, 2024 | fool.com.auAre CSL shares set for an earnings boost?January 23, 2024 | fool.com.auIs now the right time to buy CSL shares? Here's my takeJanuary 23, 2024 | theglobeandmail.comAll hands on deck for employee growth at CSLJanuary 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ansell (OtherANSLF) and CSL (OtherCMXHF)January 3, 2024 | finanznachrichten.deCSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled SyringeJanuary 2, 2024 | markets.businessinsider.comLoop Capital Markets Keeps Their Buy Rating on Carlisle Companies (CSL)December 21, 2023 | msn.comCSL worker held for 'spying' on Navy shipDecember 18, 2023 | ca.finance.yahoo.comQURE Jan 2024 25.000 callDecember 17, 2023 | ca.finance.yahoo.comQURE Jan 2024 5.000 callDecember 17, 2023 | ca.finance.yahoo.comQURE Jan 2024 25.000 putDecember 16, 2023 | ca.finance.yahoo.comQURE Jan 2024 9.000 callSee More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.63 Current Ratio2.01 Quick Ratio0.82 Sales & Book Value Annual Sales$13.31 billion Price / Sales6.65 Cash Flow$3.11 per share Price / Cash Flow29.43 Book Value$18.48 per share Price / Book4.95Miscellaneous Outstanding Shares966,190,000Free FloatN/AMarket Cap$88.45 billion OptionableNot Optionable Beta0.73 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsGSKNYSE:GSKZoetisNYSE:ZTSRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXBristol-Myers SquibbNYSE:BMYView All Competitors Should I Buy CSL Stock? CSLLY Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of CSL was last updated on Friday, March 15, 2024 at 4:18 AM. Pros Here are some ways that investors could benefit from investing in CSL Limited: CSL Limited is a well-established biopharmaceutical company with a long history dating back to 1916, indicating stability and experience in the industry. The company operates globally, with a presence in key markets such as Australia, the United States, Germany, and China, providing diversification and exposure to different economies. CSL Limited's focus on research, development, and distribution of biopharmaceuticals and vaccines positions it well to benefit from the growing demand for healthcare products worldwide. Recent developments in CSL Behring segment, offering plasma products, gene therapies, and recombinants, showcase the company's commitment to innovation and staying competitive in the market. Despite the current stock price, which can fluctuate, CSL Limited's long-term growth potential and strong market position make it an attractive investment option for investors seeking exposure to the pharmaceutical industry. Cons Investors should be bearish about investing in CSL Limited for these reasons: CSL Limited's recent short-term performance has shown minimal growth, as indicated by the FiftyTwoWeekPerformance of 0.0025, which may raise concerns about short-term returns for investors. The company's low institutional ownership percentage of 0% may suggest limited interest from larger institutional investors, potentially impacting market sentiment and liquidity. With OutstandingShares at 0, there may be concerns about the company's capital structure and potential dilution of shares in the future. The FloatSize of 0 and SharesShortedPreviousMonth of 32600 may indicate limited trading activity and short interest, which could affect stock price volatility and liquidity. CSL Limited's DaysToCover of 0.3, reflecting the number of days it would take for short sellers to cover their positions, may indicate a potential risk of short squeezes impacting the stock price. CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed in 2024? CSL's stock was trading at $97.17 on January 1st, 2024. Since then, CSLLY stock has decreased by 5.9% and is now trading at $91.43. View the best growth stocks for 2024 here. Are investors shorting CSL? CSL saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 8,700 shares, an increase of 443.8% from the February 14th total of 1,600 shares. Based on an average daily trading volume, of 42,200 shares, the short-interest ratio is currently 0.2 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.18%. Read our dividend analysis for CSLLY. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.